Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide

Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide

Enzalutamide, an approved drug for prostate cancer, acts on TMPRSS2 expression, a key mediator for SARS-CoV-2 infection. Here, the authors characterize the anti-SARS-CoV-2 effects of Enzalutamide in prostate cancer cells, lung cancer cells, human lung organoids and in hACE2-transduced Tmprss2 knocko...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Fei Li, Ming Han, Pengfei Dai, Wei Xu, Juan He, Xiaoting Tao, Yang Wu, Xinyuan Tong, Xinyi Xia, Wangxin Guo, Yunjiao Zhou, Yunguang Li, Yiqin Zhu, Xiaoyu Zhang, Zhuang Liu, Rebiguli Aji, Xia Cai, Yutang Li, Di Qu, Yu Chen, Shibo Jiang, Qiao Wang, Hongbin Ji, Youhua Xie, Yihua Sun, Lu Lu, Dong Gao
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
Science
Q
Accès en ligne:https://doaj.org/article/8cd722a7f3344c2295d560f85a3a6ec3
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Description
Résumé:Enzalutamide, an approved drug for prostate cancer, acts on TMPRSS2 expression, a key mediator for SARS-CoV-2 infection. Here, the authors characterize the anti-SARS-CoV-2 effects of Enzalutamide in prostate cancer cells, lung cancer cells, human lung organoids and in hACE2-transduced Tmprss2 knockout mice and show lack antiviral action in human lung cells and human lung organoids, likely due to the AR-independent TMPRSS2 expression in mouse and human lung epithelial cells.

Documents similaires